Table 3

Studies of the effects of angiotensin converting enzyme inhibitors on portal pressure

Author/year	No patients	Drug dose (mg)	Duration	WHVP (mm Hg)	FHVP (mm Hg)	HVPG (mm Hg)	MAP (mm Hg)
Eriksson, 198440	7	Captopril 12.5–25 mg	Single oral	22 (2) to 19 (2)	8 to 5^3-152	14 (2) to 13 (2)	93 (3) to 79 (7)^3-150

Pariente, 198523	6	Captopril 12.5 mg	Single oral	NA	NA	19.7 (3.6) to 18.8 (3.7)	87 (10.6) to 72.5 (7.3)^3-150

Ibarra, 199229	9	Captopril 25 mg	Single oral	22.9 (2.7) to 20.7 (2.4)	15 (1.8) to 12.1 (0.9)	7.58 (1.5) to 8.58 (2)	86.9 (2.6) to 77 (1.9)^3-150

Tsai, 199632	25	Captopril 18.75 mg	2 weeks	NA	NA	17.2 (1.3) to 17.5 (1.2)	88.3 (3) to 86 (4)
	25	Placebo	2 weeks	NA	NA	17.6 (1.1) to 17.8 (1.1)	86 (2) to 85 (3)

Ibarra, 199229	9	Captopril 75 mg	3 weeks	22.9 (2.7) to 18.8 (2.9)	15 (1.8) to 9.4 (0.5)	7.6 (1.5) to 9.3 (2.7)	86.9 (2.6) to 80.2 (3.7)

Svoboda, 199242	12	Enalapril 20 mg	12 weeks	25.5 (4.8) to 21.3 (4.8)^3-150	8.0 (2.8) to 8.6 (2.3)	17 (6) to 12.6 (3.4)^3-150	14.1 (4.1) to 12.5 (3.8)
	13	Placebo	12 weeks	22.8 (7.1) to 23.3 (6.7)	8.7 (4.3) to 8.2 (3.8)	14.2 (5.1) to 15.2 (3.4)	13.6 (4) to 12.8 (4.2)

Chiang, 199541	20	Enalaprilat 2.5 mg	Single intravenous	32.1 (5.1) to 25.6 (7.2)^3-150	11.2 (3.7) to 10.7 (3.7)^3-150	21 (4.3) to 16.1 (4.5)^3-150	94.1 (11.2) to 85.6(13.8)^3-150

Values are mean (SD).
NA, data not available; WHVP, wedged hepatic venous pressure; FHVP, free hepatic venous pressure; HVPG, hepatic venous pressure gradient; MAP, mean arterial pressure.
↵3-150 Statistically significant.
↵3-152 Numbers obtained by measurement and/or calculation on figures.